CN113663069A - Hollow mesoporous polydopamine nano-carrier, preparation method and application thereof - Google Patents
Hollow mesoporous polydopamine nano-carrier, preparation method and application thereof Download PDFInfo
- Publication number
- CN113663069A CN113663069A CN202110960482.5A CN202110960482A CN113663069A CN 113663069 A CN113663069 A CN 113663069A CN 202110960482 A CN202110960482 A CN 202110960482A CN 113663069 A CN113663069 A CN 113663069A
- Authority
- CN
- China
- Prior art keywords
- carrier
- mesoporous
- hollow mesoporous
- nano
- polydopamine nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Silicon Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a hollow mesoporous polydopamine nano-carrier, a preparation method and application thereof, wherein mesoporous silicon dioxide is used as a hard template to prepare monodisperse mSiO with small particle size under the joint participation of dopamine hydrochloride, ammonia water and F1272@ PDA nanoparticles; using absolute ethyl alcohol and acetone as mixed solvent, removing template agent F127, and utilizing Na2CO3Etching to remove the mesoporous silicon dioxide used as a hard template to prepare the hollow mesoporous polydopamine nano-carrier with good dispersity and uniform particle size. Control of the hollow mesoporous polydopamine nanocarriersThe size of the hollow shell and the size of the pore diameter endow the nano drug carrier with excellent biocompatibility and larger specific surface area, and the two advantages can be used as an ideal carrier of potential clinical anticancer drugs and imaging agents.
Description
Technical Field
The invention relates to the technical field of nano materials, in particular to a hollow mesoporous polydopamine nano carrier, a preparation method and application thereof.
Background
Cancer is undoubtedly a major threat to human health worldwide. Although a large number of anticancer drugs are currently available, chemotherapy still faces insurmountable challenges as the primary means of clinical cancer therapy, such as drug resistance and serious side effects.
In recent years, many existing chemotherapeutic drugs (such as Dox) need a certain carrier for targeted tumor delivery to achieve the desired therapeutic effect in order to reduce the side effects and damage to normal cells of the chemotherapeutic drugs and increase their biocompatibility and high penetration and retention effects. However, many existing nano-carriers have certain defects, such as poor biocompatibility, low drug loading rate and the like, and only serve as one carrier, and cannot play a therapeutic role. For example mesoporous silica (mSiO)2) Nanoparticles, due to their mesoporous nature with high specific surface area and tunable pore structure, are suitable as multifunctional delivery vehicles for drugs and imaging agents. However, silica also exhibits significant disadvantages including complicated synthesis and poor biodegradability, and in addition does not exert any therapeutic effect, thus greatly hindering its clinical application.
Polydopamine (PDA), a melanin-like polymer, is recognized as one of the most attractive biomedical applications due to its inherent biocompatibility, ease of preparation, and photothermal therapy with strong Near Infrared (NIR) absorption. However, conventional PDA nanoparticles are typically non-porous or mesoporous and thus exhibit limited drug loading capacity. In addition, drugs adsorbed on the surface of nanoparticles are easily shed under complex physiological conditions. Therefore, Hollow Mesoporous Polydopamine (HMPDA) nanoparticles that can stably load a large amount of drug into their cavities have broader prospects in drug delivery. By virtue of the hollow structure and the strong capability of converting near-infrared two-region photons into local heat, the HMPDA nano-carrier not only can provide effective drug encapsulation, but also shows effective photothermal treatment effect, and is expected to be applied to clinical tumor treatment in the future.
Disclosure of Invention
The invention aims to provide a hollow mesoporous polydopamine nano-carrier, a preparation method and application thereof, so as to solve the problems in the prior art.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a preparation method of a hollow mesoporous polydopamine nano-carrier comprises the following steps:
s1, preparing mesoporous silica: adding tetraethyl orthosilicate serving as a raw material into a mesoporous template reaction solution of hexadecyl trimethyl ammonium p-toluenesulfonate mixed with triethanolamine and 1-butyl 3-methyl-imidazole trifluoromethanesulfonate, and washing out the mesoporous template after reaction to prepare mesoporous silicon dioxide;
s2, preparing mSiO2@ PDA, namely dispersing the mesoporous silica obtained in the step S1 and a template F127 into a solution, reacting with a dopamine hydrochloride solution in an alkaline environment, and washing and drying a product obtained after the reaction to obtain mSiO2@ PDA;
s3, preparing a hollow mesoporous polydopamine nano-carrier: and (4) carrying out oscillation reaction on the product mSiO2@ PDA obtained in the step (S2) by adopting a cosolvent and a sodium carbonate solution in sequence to remove F127 and a silicon dioxide core on the mSiO2@ PDA, and finally obtaining the hollow mesoporous polydopamine nano-carrier.
Preferably, step S1 specifically includes:
firstly, 0.96g of hexadecyl trimethyl ammonium p-toluenesulfonate, 0.105g of triethanolamine and 10mg of 1-butyl 3-methyl-imidazole trifluoromethanesulfonate are mixed in 50-60mL of deionized water and stirred for 1h at 70-90 ℃; then, 7.8mL of tetraethyl orthosilicate is quickly added into the mixed system, and after stirring and reacting for 2-2.5h at 70-90 ℃, products obtained after reaction are separated and washed by ethanol and water respectively; dispersing the washed product in absolute ethyl alcohol, stirring for 24h, separating, washing with ethyl alcohol, and finally drying the centrifugal product to obtain white solid powder, namely the mesoporous silicon dioxide.
Preferably, step S2 specifically includes:
firstly, dispersing 50-60mg of mesoporous silica prepared in the step S1 and 200-220mg of template agent F127 in 35-50mL of deionized water, and performing ultrasonic treatment to uniformly disperse the mesoporous silica and the template agent F127 to obtain a mesoporous silica system; dissolving 50mg of dopamine hydrochloride into 15-20mL of absolute ethanol, then adding the dopamine solution into the mesoporous silica system, adjusting the pH of the system to 8.5, carrying out a reaction for 24 hours at normal temperature in a dark place, centrifuging the reaction system, washing the reaction system with ethanol and water for multiple times respectively, and finally drying the centrifuged product to obtain brown powder, namely mSiO2@PDA。
Preferably, the manner of adjusting the pH of the system is to add ammonia water.
Preferably, step S3 specifically includes:
s31, removing F127: mixing the mSiO2@ PDA powder is uniformly dispersed in a cosolvent of ethanol and acetone, and mSiO is controlled2The mass fraction of @ PDA is 15%, and the adding proportion of ethanol and acetone is 3: 1; stirring for 24h at normal temperature, centrifuging, washing to obtain a centrifugal product, and transferring the centrifuged and washed centrifugal product to a vacuum oven at 60-80 ℃ for drying;
s32, removing SiO2And (3) nucleus: dispersing the product of the last step of removing F127 in Na with the concentration of 2mol/L2CO3In the solution, shaking and reacting for 6-7h in a constant temperature shaking table at 60-70 DEG CAnd centrifuging and washing to obtain a centrifugal product, and transferring the centrifuged and washed centrifugal product to a vacuum oven at 60-80 ℃ for drying to obtain the hollow mesoporous polydopamine nano-carrier.
The invention also aims to provide the hollow mesoporous polydopamine nano-carrier prepared by the preparation method of the hollow mesoporous polydopamine nano-carrier.
The last purpose of the invention is also to apply the hollow mesoporous polydopamine nano-carrier in clinical tumor drugs.
The invention proposes: firstly, mesoporous silicon dioxide is used as a hard template, and under the joint participation of dopamine hydrochloride, ammonia water and F127, the monodisperse mSiO with small particle size is prepared2@ PDA nanoparticles; ② taking absolute ethyl alcohol and acetone as mixed solvent, removing template agent F127, and then utilizing Na2CO3Etching to remove the mesoporous silicon dioxide used as a hard template to prepare the hollow mesoporous polydopamine nano-carrier with good dispersity and uniform particle size.
The invention has the beneficial effects that:
the invention discloses a hollow mesoporous polydopamine nano-carrier, a preparation method and application thereof, the method adopts a hard template method to prepare HMPDA, the synthesis process is simple and easy to implement, the conditions are mild, the generated nano-carrier has good dispersibility and uniform particle size distribution; secondly, the HMPDA hollow mesoporous nano carrier prepared by taking mesoporous silicon dioxide as a core and polydopamine as a shell has high biological safety; meanwhile, the hollow mesoporous polydopamine nano-drug carrier prepared by the invention can convert photons of 1064nm laser into local heat, so that the hollow mesoporous polydopamine nano-drug carrier can be used as an excellent photo-thermal treatment drug; in addition, the HMPDA prepared by the method has a hollow mesoporous structure and can form pi-pi conjugation with a plurality of medicines, so that the nano-medicine carrier has high medicine carrying rate and stability. The last point is that dopamine is one of the most common polyphenols, and polydopamine also has a specific catechol structure, so that the polydopamine is extremely easy to form a coordination relationship with various metal ions, and a coordination network of drug-metal ion-polydopamine is formed, so that the loaded anticancer is further stabilizedDrugs, in addition, supported metal ions such as Cu+/2+、Fe2+/3+、Mn2+/4+The Fenton reaction-based nano platform can be used for chemical kinetic treatment and in-vivo imaging and can be used as a potential diagnosis and treatment integrated nano platform.
Drawings
FIG. 1 is a scanning electron microscope image of mesoporous silica prepared by the Stober method.
FIG. 2 is a transmission electron microscope photograph of mesoporous silica.
FIG. 3 is mSiO2Transmission electron microscope pictures of @ PDA.
Fig. 4 is a transmission electron microscope picture of the hollow mesoporous polydopamine nano-carrier.
Fig. 5 is a nitrogen adsorption and desorption curve of the hollow mesoporous polydopamine nano-carrier.
Fig. 6 is a pore size distribution curve of the hollow mesoporous polydopamine nano-carrier.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to the accompanying drawings. It should be understood that the detailed description and specific examples, while indicating the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1
The embodiment provides a preparation method of a hollow mesoporous polydopamine nano-carrier, which specifically comprises the following steps:
(1) mesoporous silica (mSiO)2) The preparation of (1): 0.96g of cetyltrimethylammonium p-toluenesulfonate, 0.105g of triethanolamine and 10mg of 1-butyl 3-methyl-imidazole trifluoromethanesulfonate were first mixed in 50mL of deionized water and stirred for 1h at 80 ℃. Then, 7.8mL of tetraethyl orthosilicate was quickly added to the above mixed system, and after stirring the reaction at 80 ℃ for 2 hours, the product was centrifuged at 11000r/min for 10 minutes and washed 2 times with ethanol and water, respectively. In order to remove the template hexadecyl trimethyl p-toluene ammonium sulfonate, the product after centrifugal washing is dispersed in 100mL of absolute ethyl alcohol, after stirring for 24h, the product is centrifuged at 11000r/min for 10min and washed with ethyl alcohol for 2 times,and finally transferring the centrifugal product to a vacuum oven at 60 ℃ for drying to obtain white solid powder, namely the mesoporous silicon dioxide.
(2)mSiO2Preparation of @ PDA, where "@" indicates coating: firstly, 50mg of mesoporous silica prepared in the first step and 200mg of template agent F127 are dispersed in 35mL of deionized water, and the mesoporous silica and the template agent F127 are uniformly dispersed by ultrasonic treatment. Dissolving 50mg dopamine hydrochloride in 15mL absolute ethyl alcohol, adding the dopamine hydrochloride into the silicon dioxide system, finally adding 0.6mL ammonia water to adjust the pH value of the system to 8.5, reacting at normal temperature in a dark place for 24 hours under vigorous stirring, centrifuging at 11000r/min for 10min, washing with ethanol and water for 2 times respectively, and finally transferring the centrifugal product to a vacuum oven at 60 ℃ for drying to obtain brown powder, namely mSiO2@PDA。
(3) Preparing a hollow mesoporous polydopamine nano-carrier: first to remove F127, 15mg of mSiO2The @ PDA powder is dispersed in a cosolvent of 33mL of ethanol and 17mL of acetone, stirred at normal temperature for 24h after being uniformly dispersed by ultrasonic, then centrifuged at 11000r/min for 10min and washed with deionized water and absolute ethanol respectively for 2 times, and the centrifuged product is transferred to a vacuum oven at 60 ℃ to be dried.
Secondly to remove SiO2Core, 10mg of the product from the last step of removing F127 was dispersed in 50mL of Na having a concentration of 2mol/L2CO3In the solution, shaking and reacting for 6h in a constant temperature shaking table at 60 ℃, then centrifuging for 10min at 11000r/min, washing for 2 times by using deionized water and absolute ethyl alcohol respectively, and transferring the centrifugal product to a vacuum oven at 60 ℃ for drying to obtain the hollow mesoporous polydopamine nano-carrier.
Example 2
The embodiment provides a preparation method of a hollow mesoporous polydopamine nano-carrier, which specifically comprises the following steps:
(1) mesoporous silica (mSiO)2) The preparation of (1): 0.96g of cetyltrimethylammonium p-toluenesulfonate, 0.105g of triethanolamine and 10mg of 1-butyl 3-methyl-imidazole trifluoromethanesulfonate were first mixed in 60mL of deionized water and stirred at 70 ℃ for 1 h. Then, 7.8mL of tetraethyl orthosilicate is quickly added into the mixed system, and after the mixture is stirred and reacts for 2.5 hours at 70 ℃, the product is centrifuged at 11000r/min10min and 2 washes with ethanol and water, respectively. In order to remove the template ammonium hexadecyltrimethyl p-toluenesulfonate, dispersing the product after centrifugal washing in 100mL of absolute ethanol, stirring for 24h, centrifuging at 11000r/min for 10min, washing with ethanol for 2 times, and finally transferring the centrifugal product to a vacuum oven at 80 ℃ for drying to obtain white solid powder, namely the mesoporous silicon dioxide.
(2)mSiO2Preparation of @ PDA, where "@" indicates coating: firstly, 60mg and 220mg of mesoporous silica prepared in the first step and a template agent F127 are dispersed in 50mL of deionized water, and the mesoporous silica and the template agent F127 are uniformly dispersed by ultrasonic treatment. Dissolving 50mg dopamine hydrochloride in 20mL absolute ethyl alcohol, adding the dopamine hydrochloride into the silicon dioxide system, finally adding 0.6mL ammonia water to adjust the pH value of the system to 8.5, reacting at normal temperature in a dark place for 24 hours under vigorous stirring, centrifuging at 11000r/min for 10min, washing with ethanol and water for 2 times respectively, and finally transferring the centrifugal product to a vacuum oven at 60 ℃ for drying to obtain brown powder, namely mSiO2@PDA。
(3) Preparing a hollow mesoporous polydopamine nano-carrier: first to remove F127, 15mg of mSiO2The @ PDA powder is dispersed in a cosolvent of 33mL of ethanol and 17mL of acetone, stirred at normal temperature for 24h after being uniformly dispersed by ultrasonic, then centrifuged at 11000r/min for 10min and washed with deionized water and absolute ethanol respectively for 2 times, and the centrifuged product is transferred to a vacuum oven at 60 ℃ to be dried.
Secondly to remove SiO2Core, 10mg of the product from the last step of removing F127 was dispersed in 50mL of Na having a concentration of 2mol/L2CO3In the solution, shaking and reacting for 7h in a constant temperature shaking table at 70 ℃, then centrifuging for 10min at 11000r/min, washing for 2 times by using deionized water and absolute ethyl alcohol respectively, and transferring the centrifugal product to a vacuum oven at 60 ℃ for drying to obtain the hollow mesoporous polydopamine nano-carrier.
Example 3
The embodiment discloses a preparation method of a hollow mesoporous polydopamine nano-carrier, which specifically comprises the following steps:
(1) mesoporous silica (mSiO)2) The preparation of (1): first 0.96g of cetyltrimethylammonium p-toluenesulfonate, 0.105g of triethanolamine and 10mg of 1-butaneThe 3-methyl-imidazole trifluoromethanesulfonate was mixed in 55mL of deionized water and stirred at 90 ℃ for 1 h. Then, 7.8mL of tetraethyl orthosilicate was quickly added to the above mixed system, and after stirring and reacting for 2 hours at 90 ℃, the product was centrifuged at 11000r/min for 10 minutes and washed 2 times with ethanol and water, respectively. In order to remove the template ammonium hexadecyltrimethyl p-toluenesulfonate, dispersing the product after centrifugal washing in 100mL of absolute ethanol, stirring for 24h, centrifuging at 11000r/min for 10min, washing with ethanol for 2 times, and finally transferring the centrifugal product to a vacuum oven at 70 ℃ for drying to obtain white solid powder, namely the mesoporous silicon dioxide.
(2)mSiO2Preparation of @ PDA, where "@" indicates coating: firstly, 55mg of mesoporous silica prepared in the first step and 210mg of template F127 are dispersed in 45mL of deionized water, and the mesoporous silica and the template F127 are uniformly dispersed by ultrasonic treatment. Dissolving 50mg dopamine hydrochloride in 20mL absolute ethyl alcohol, adding the dopamine hydrochloride into the silicon dioxide system, finally adding 0.6mL ammonia water to adjust the pH value of the system to 8.5, reacting at normal temperature in a dark place for 24 hours under vigorous stirring, centrifuging at 10000r/min for 20 minutes, washing with ethanol and water for 2 times respectively, transferring the centrifuged product to a vacuum oven at 70 ℃ for drying, and obtaining brown powder which is mSiO2@PDA。
(3) Preparing a hollow mesoporous polydopamine nano-carrier: first to remove F127, 15mg of mSiO2The @ PDA powder is dispersed in a cosolvent of 33mL of ethanol and 17mL of acetone, stirred at normal temperature for 24h after being uniformly dispersed by ultrasonic, then centrifuged at 11000r/min for 10min and washed by deionized water and absolute ethanol for 3 times respectively, and the centrifuged product is transferred to a vacuum oven at 70 ℃ for drying.
Secondly to remove SiO2Core, 10mg of the product from the last step of removing F127 was dispersed in 50mL of Na having a concentration of 2mol/L2CO3In the solution, shaking and reacting for 6.5h in a constant temperature shaking table at 65 ℃, then centrifuging for 10min at 11000r/min, washing for 2 times by using deionized water and absolute ethyl alcohol respectively, and transferring the centrifugal product to a vacuum oven at 60 ℃ for drying to obtain the hollow mesoporous polydopamine nano-carrier.
The mesoporous silica prepared in example 1, mSiO was used2@ PDA and hollow mesoporous polydopamine nano-carrierScanning with a transmission electron microscope, as shown in fig. 2, fig. 3 and fig. 4, respectively, fig. 1 is a scanning electron microscope picture of the prepared mesoporous silica, and it can be seen from the picture that the prepared mesoporous silica has regular morphology, better dispersibility and a particle size of about 80 nm; FIG. 2 is a corresponding transmission electron microscope image, from which it can be seen that the prepared silica has a distinct mesoporous structure with a pore size of about 15 nm. The apparent core-shell structure can be seen in FIG. 3, and furthermore the mSiO synthesized2The @ PDA has better dispersibility and the particle size is about 120nm, which proves that the mesoporous silicon dioxide is successfully coated by utilizing the polydopamine; fig. 4 is a transmission electron microscope picture of the hollow mesoporous polydopamine nano-carrier after the silica template is removed, from which a distinct hollow structure can be seen, and the shell thickness of the hollow mesoporous polydopamine nano-carrier is about 20 nm. Performing an adsorption test on the pore diameter of the prepared hollow mesoporous polydopamine nano-carrier, wherein fig. 5 is a nitrogen adsorption and desorption curve of the hollow mesoporous polydopamine nano-carrier, and referring to the IUPAC nomenclature, the curve belongs to an IV-type isotherm and has a typical mesoporous structure; fig. 6 is a corresponding pore size distribution curve. From fig. 5 and fig. 6, it can be concluded that the specific surface area and the pore diameter of the hollow mesoporous polydopamine nano-carrier are 77.174m respectively2G and 4.4793 nm. Therefore, the hollow mesoporous polydopamine nano-carrier is successfully prepared by adopting the preparation method disclosed by the invention.
Example 4
By using the preparation methods of example 1/example 2/example 3, a hollow mesoporous polydopamine nano-carrier is prepared by using a natural product dopamine as a raw material, silica as a hard template, polyether F127 (polyoxyethylene polyoxypropylene ether block copolymer) as a template agent and designing a core-shell structure. The hollow mesoporous polydopamine nano-carrier controls the size of a hollow shell layer and the size of a pore diameter, can endow the nano-drug carrier with excellent biocompatibility and larger specific surface area, and can be used as an ideal carrier of potential clinical anticancer drugs and imaging agents.
By adopting the technical scheme disclosed by the invention, the following beneficial effects are obtained:
the invention discloses a hollow mesoporous polydopamine nano-carrier, a preparation method and application thereof, the method adopts a hard template method to prepare HMPDA, the synthesis process is simple and easy to implement, the conditions are mild, the generated nano-carrier has good dispersibility and uniform particle size distribution; secondly, the HMPDA hollow mesoporous nano carrier prepared by taking mesoporous silicon dioxide as a core and polydopamine as a shell has high biological safety; meanwhile, the hollow mesoporous polydopamine nano-drug carrier prepared by the invention can convert photons of 1064nm laser into local heat, so that the hollow mesoporous polydopamine nano-drug carrier can be used as an excellent photo-thermal treatment drug; in addition, the HMPDA prepared by the method has a hollow mesoporous structure and can form pi-pi conjugation with a plurality of medicines, so that the nano-medicine carrier has high medicine carrying rate and stability. The last point is that dopamine is one of the most common polyphenols, polydopamine also has a specific catechol structure, which makes it extremely easy to form coordination relationship with various metal ions, so that an organic coordination network of drug-metal ion-polydopamine is formed to further stabilize the loaded anticancer drug, and in addition, the loaded metal ion such as Cu+/2+、Fe2+/3+、Mn2+/4+The Fenton reaction-based nano platform can be used for chemical kinetic treatment and in-vivo imaging and can be used as a potential diagnosis and treatment integrated nano platform.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and improvements can be made without departing from the principle of the present invention, and such modifications and improvements should also be considered within the scope of the present invention.
Claims (7)
1. A preparation method of a hollow mesoporous polydopamine nano-carrier is characterized by comprising the following steps:
s1, preparing mesoporous silica: adding tetraethyl orthosilicate serving as a raw material into a mesoporous template reaction solution of hexadecyl trimethyl ammonium p-toluenesulfonate mixed with triethanolamine and 1-butyl 3-methyl-imidazole trifluoromethanesulfonate, and washing out the mesoporous template after reaction to prepare mesoporous silicon dioxide;
S2,mSiO2the preparation of @ PDA comprises the steps of dispersing the mesoporous silica obtained in the step S1 and a template F127 in a solution, reacting with a dopamine hydrochloride solution in an alkaline environment, washing and drying a product obtained after the reaction to obtain mSiO2@PDA；
S3, preparing a hollow mesoporous polydopamine nano-carrier: the product obtained in the step S2 is mSiO2The @ PDA adopts a cosolvent and a sodium carbonate solution to carry out oscillation reaction respectively to remove the mSiO2F127 on the @ PDA and a silicon dioxide core to finally obtain the hollow mesoporous polydopamine nano-carrier.
2. The method for preparing the hollow mesoporous polydopamine nano-carrier according to claim 1, wherein the step S1 specifically includes:
firstly, 0.96g of hexadecyl trimethyl ammonium p-toluenesulfonate, 0.105g of triethanolamine and 10mg of 1-butyl 3-methyl-imidazole trifluoromethanesulfonate are mixed in 50-60mL of deionized water and stirred for 1h at 70-90 ℃; then, 7.8mL of tetraethyl orthosilicate is quickly added into the mixed system, and after stirring and reacting for 2-2.5h at 70-90 ℃, products obtained after reaction are separated and washed by ethanol and water respectively; dispersing the washed product in absolute ethyl alcohol, stirring for 24h, separating, washing with ethyl alcohol, and finally drying the centrifugal product to obtain white solid powder, namely the mesoporous silicon dioxide.
3. The method for preparing the hollow mesoporous polydopamine nano-carrier according to claim 1, wherein the step S2 specifically includes:
firstly, dispersing 50-60mg of mesoporous silica prepared in the step S1 and 200-220mg of template agent F127 in 35-50mL of deionized water, and performing ultrasonic treatment to uniformly disperse the mesoporous silica and the template agent F127 to obtain a mesoporous silica system; then 50mg of dopamine hydrochloride is dissolved in 15-20mL of absolute ethyl alcohol, and then the dopamine is dissolvedAdding the solution into the mesoporous silica system, adjusting the pH of the system to 8.5, carrying out a reaction for 24 hours at normal temperature in a dark place, centrifuging the reaction system, washing the reaction system with ethanol and water for multiple times, and finally drying the centrifuged product to obtain brown powder, namely mSiO2@PDA。
4. The method for preparing the hollow mesoporous polydopamine nano-carrier according to claim 3, wherein the pH of the system is adjusted by adding ammonia water.
5. The method for preparing the hollow mesoporous polydopamine nano-carrier according to claim 1, wherein the step S3 specifically includes:
s31, removing F127: mixing the mSiO2@ PDA powder is uniformly dispersed in a cosolvent of ethanol and acetone, and mSiO is controlled2The mass fraction of @ PDA is 15%, and the adding proportion of ethanol and acetone is 3: 1; stirring for 24h at normal temperature, centrifuging, washing to obtain a centrifugal product, and transferring the centrifuged and washed centrifugal product to a vacuum oven at 60-80 ℃ for drying;
s32, removing SiO2And (3) nucleus: dispersing the product of the last step of removing F127 in Na with the concentration of 2mol/L2CO3In the solution, shaking and reacting for 6-7h in a constant-temperature shaking table at 60-70 ℃, then centrifuging and washing to obtain a centrifugal product, and transferring the centrifuged and washed centrifugal product to a vacuum oven at 60-80 ℃ for drying to obtain the hollow mesoporous polydopamine nano-carrier.
6. The hollow mesoporous polydopamine nano-carrier prepared by the preparation method of the hollow mesoporous polydopamine nano-carrier according to any one of claims 1 to 5.
7. The hollow mesoporous polydopamine nano-carrier of claim 6, for use in clinical tumor drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110960482.5A CN113663069A (en) | 2021-08-20 | 2021-08-20 | Hollow mesoporous polydopamine nano-carrier, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110960482.5A CN113663069A (en) | 2021-08-20 | 2021-08-20 | Hollow mesoporous polydopamine nano-carrier, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113663069A true CN113663069A (en) | 2021-11-19 |
Family
ID=78544523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110960482.5A Pending CN113663069A (en) | 2021-08-20 | 2021-08-20 | Hollow mesoporous polydopamine nano-carrier, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113663069A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114276681A (en) * | 2022-01-14 | 2022-04-05 | 南开大学 | Polydopamine microsphere with multilevel mesoporous structure and preparation method thereof |
| CN114716628A (en) * | 2022-04-08 | 2022-07-08 | 河源诚展科技有限公司 | LDI photosensitive dry film and preparation method thereof |
| CN116271092A (en) * | 2023-03-02 | 2023-06-23 | 四川大学 | Shape-controllable nanoscale hollow carbon sphere drug carrier and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103613101A (en) * | 2013-10-31 | 2014-03-05 | 华东师范大学 | Preparation method of mesoporous silica nanosphere having dendrimer-like open-framework structure |
-
2021
- 2021-08-20 CN CN202110960482.5A patent/CN113663069A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103613101A (en) * | 2013-10-31 | 2014-03-05 | 华东师范大学 | Preparation method of mesoporous silica nanosphere having dendrimer-like open-framework structure |
Non-Patent Citations (2)
| Title |
|---|
| CAIHONG TAO等: "Preparation and adsorption performance research of large-volume hollow mesoporous polydopamine microcapsules", 《MRS COMMUNICATIONS》 * |
| ZOFIA E. SIWICKA等: "Synthetic Porous Melanin", 《JACS》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114276681A (en) * | 2022-01-14 | 2022-04-05 | 南开大学 | Polydopamine microsphere with multilevel mesoporous structure and preparation method thereof |
| CN114276681B (en) * | 2022-01-14 | 2023-12-22 | 南开大学 | Polydopamine microsphere with multi-stage mesoporous structure and preparation method thereof |
| CN114716628A (en) * | 2022-04-08 | 2022-07-08 | 河源诚展科技有限公司 | LDI photosensitive dry film and preparation method thereof |
| CN114716628B (en) * | 2022-04-08 | 2022-09-20 | 广东诚展科技股份有限公司 | LDI photosensitive dry film and preparation method thereof |
| CN116271092A (en) * | 2023-03-02 | 2023-06-23 | 四川大学 | Shape-controllable nanoscale hollow carbon sphere drug carrier and preparation method thereof |
| CN116271092B (en) * | 2023-03-02 | 2024-02-20 | 四川大学 | Shape-controllable nanoscale hollow carbon sphere drug carrier and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113663069A (en) | Hollow mesoporous polydopamine nano-carrier, preparation method and application thereof | |
| CN107936266B (en) | Cellulose/black phosphorus nanosheet composite hydrogel and preparation method thereof | |
| WO2019095751A1 (en) | Cellulose/two-dimensional layered material composite hydrogel and preparation method therefor | |
| CN102786061B (en) | Preparation method of hollow mesoporous silica nanoparticle | |
| CN107019802B (en) | Flexible hollow mesoporous organic silicon oxide nanocapsule material and preparation method thereof | |
| CN111671914B (en) | Near infrared light response nanoparticle and controlled release system | |
| CN111265533A (en) | Preparation method of core-shell nanoparticles based on lipid membrane and metal organic framework | |
| WO2019114066A1 (en) | Black phosphorus-based hydrogel near-infrared light-controllable drug release system and preparation method therefor | |
| CN104491866A (en) | Copper sulphide/mesoporous silicon dioxide core-shell nanoparticles as well as preparation and application thereof | |
| CN111137915A (en) | Composite nano material with mesoporous silica coated with nano particles and preparation method and application thereof | |
| CN113289030A (en) | Preparation method of targeted long-circulating nano-drug carrier for photothermal synergistic chemotherapy | |
| CN108084460A (en) | A kind of cellulose/black phosphorus quantum dot composite hydrogel and preparation method thereof | |
| CN109806240A (en) | Polymer-modified mesoporous carbon nanoparticle and its preparation and application | |
| CN104189917A (en) | Preparation method of doxorubicin-containing graphene oxide medicine-carrying composite material | |
| CN108030922B (en) | Temperature-sensitive gold nanocage, preparation method and application thereof, drug-loading temperature-sensitive gold nanocage and preparation method thereof | |
| CN114949254A (en) | Hollow mesoporous cubic ZIF-8 nano carrier, preparation method and application thereof | |
| Siva Gangi Reddy et al. | Fabrication of aminosilanized halloysite based floating biopolymer composites for sustained gastro retentive release of curcumin | |
| CN114010799B (en) | Targeting degradable nano-drug carrier for photo-thermal synergistic chemotherapy and preparation method thereof | |
| CN111420056A (en) | Nanoparticle for releasing P L GA shell through microwave touch, preparation method and application thereof | |
| CN111924851B (en) | Silicon dioxide nano material with umbrella-shaped dendritic structure and preparation method thereof | |
| CN110302146B (en) | Preparation and application of injectable attapulgite composite supramolecular hydrogel | |
| CN110478320B (en) | S-propargyl cysteine-loaded mesoporous silicon dioxide preparation and preparation method thereof | |
| CN107149683B (en) | Preparation method and application of mesoporous silica nanoparticles with bell structure | |
| CN109223711B (en) | Method for controlling particle size of curcumenol derivative PEG-PLA micelle by thin film hydration method | |
| CN108578384B (en) | Encapsulated Bi2S3Nano-particle alginate microsphere and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |